News and reporting on prostate cancer.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
One study characterized an allele linked to aggressive prostate cancer, while the other explored the range of structural variations within metastatic disease.
The work is being funded with $26.5 million from the 21st Century Cures Cancer Moonshot Initiative.
Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.
Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.
The researchers used 10X Genomics' linked-read genome sequencing approach to home in on rearrangements that affect the androgen receptor locus and its enhancer.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.
The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.
In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.